MicroPulse P3® Device
For Non-Incisional Glaucoma Treatment With MicroPulse® Transscleral Laser Therapy
- A success rate of 60% to 80%1-17
- Achieves IOP reduction of 30% to 45%1, 3, 6, 9-15, 17, 18
- Durability of up to 72 months with 3 retreatments19
- Over 120,000 patients treated in 60 countries
- Leaves future treatment options open
Re-Thinking Glaucoma Care
MICROPULSE® TRANSSCLERAL LASER THERAPY (TLT)
A compelling combination of safety, effectiveness, durability and repeatability all in a nonincisional approach to Glaucoma Care. MicroPulse Transscleral Laser Therapy via the MicroPulse P3 Device offers you and your patients a treatment paradigm which can be introduced prior to, in conjunction with and following all other available glaucoma treatment options, and the ability to treat at several different time points throughout the course of the disease.
- A success rate of 60% to 80%1-17
- Leaves future treatment options open
- Achieves IOP reduction of 30% to 45%1, 3, 6, 9-15, 17, 18
- For moderate, severe, and refractory glaucoma
- Durability of up to 72 months with 3 retreatments19
- Used in 38 of the 39 best hospitals in the United States*
- Reduction in drug burden in eye drops and oral medications1-4, 6-13, 18
- Revised probe now available with improved ease of use, visualization, fit, and coupling
- Low cost per mmHg reduction versus other interventions
- Limited amount of immediate follow-up
- Patient downtime is significantly low
- Low investment for high utility
- Economic savings to patients
- Covered under CPT 66710 ($400 -$1,934)
Glaucoma Therapy Device Options
The patented MicroPulse P3® Glaucoma Device, G-Probe® Device and G-Probe Illuminate® are used to deliver laser energy for the treatment of glaucoma.
What is the treatment technique for the MicroPulse P3 (MP3) Probe?
What is the treatment technique for the G-Probe?
